Griffin J H, Fernández J A, Deguchi H
Department of Molecular and Experimental Medicine, Scripps Research Institute, La Jolla, CA 92037, USA.
Thromb Haemost. 2001 Jul;86(1):386-94.
Regulation of hemostasis and thrombosis involves numerous plasma factors that contribute to procoagulant and anticoagulant pathways. Lipid-containing surfaces provide sites where both procoagulant and anticoagulant enzymes, cofactors and substrates are assembled to express their activities. Plasma and lipoproteins can contribute to either procoagulant or anticoagulant reactions. Procoagulant lipids/lipoproteins include triglyceride-rich particles in plasma and oxidized low density lipoprotein (LDL) which can accelerate activation of prothrombin, factor X and factor VII. Potentially anticoagulant lipids and lipoproteins, each of which enhances inactivation of factor Va by activated protein C, include phosphatidylethanolamine, cardiolipin, the neutral glycosphingolipids glucosylceramide and Gb3 ceramide (CD77), and high density lipoprotein (HDL). Remarkably, treatment of hyperlipidemia with statins not only lowers lipids but also provides antithrombotic effects whose mechanisms remain to be clarified. We hypothesize that procoagulant and anticoagulant lipids and lipoproteins in plasma may contribute to a Yin-Yang balance that helps influence the up-regulation and down-regulation of thrombin generation.
止血和血栓形成的调节涉及众多血浆因子,这些因子参与促凝和抗凝途径。含脂表面为促凝和抗凝酶、辅因子及底物提供了组装位点,以发挥它们的活性。血浆和脂蛋白可参与促凝或抗凝反应。促凝脂质/脂蛋白包括血浆中富含甘油三酯的颗粒以及氧化型低密度脂蛋白(LDL),它们可加速凝血酶原、因子X和因子VII的激活。具有潜在抗凝作用的脂质和脂蛋白,其中每一种都可增强活化蛋白C对因子Va的灭活作用,包括磷脂酰乙醇胺、心磷脂、中性糖鞘脂葡萄糖神经酰胺和Gb3神经酰胺(CD77)以及高密度脂蛋白(HDL)。值得注意的是,用他汀类药物治疗高脂血症不仅能降低血脂,还具有抗血栓形成作用,但其机制尚待阐明。我们推测,血浆中的促凝和抗凝脂质及脂蛋白可能有助于阴阳平衡,从而影响凝血酶生成的上调和下调。